OptimizeRx Corporation Earnings Recaps
Q3 2025
Nov 7, 2025
OptimizeRx reported a robust Q3 2025 with revenues of $26.1 million, reflecting a 22% year-over-year growth, and an adjusted EBITDA of $5.1 million, exceeding expectations.
Key takeaways
- Revenue guidance for FY 2025 has been raised to $105-$109 million, with adjusted EBITDA now expected between $16-$19 million.
- Average revenue from the top 5 customers has grown beyond $11 million, demonstrating strong client relationships and engagement.
- The company continues to reduce its debt, paying down an additional $2 million, and does not anticipate needing to access equity capital markets in the near future.
- Gross margin improved to 67.2%, driven by a favorable product and channel mix, alongside disciplined cost management efforts.
- Initial guidance for FY 2026 indicates revenue of $118-$124 million and adjusted EBITDA of $19-$22 million, signaling confidence in future growth.